Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:40 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT05966233 · Fondazione Italiana Linfomi - ETS · PHASE2 · withdrawn · last registry update 2024-05-21 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision” | – | Registry record, Fondazione Italiana Linfomi - ETS |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MS4A1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2025-05-14Phase 3 first posted: BeOne Medicines, BGB-16673 + Bendamustine (NCT06970743)
- 2025-04-24Phase 3 first posted: BeOne Medicines, Sonrotoclax + Obinutuzumab (NCT06943872)
- 2025-04-20Results posted on the registry: National Cancer Institute (NCI), Obinutuzumab + Prednisone (NCT05211336)
- 2025-04-18Results posted on the registry: University of Washington, Pembrolizumab + Rituximab (NCT03401853)
- 2025-04-17Results posted on the registry: Hoffmann-La Roche, Obinutuzumab + Venetoclax (NCT04285567)
- 2025-04-16Results posted on the registry: Hoffmann-La Roche, Ocrelizumab (NCT04998851)
- 2025-03-12Results posted on the registry: Dana-Farber Cancer Institute, Obinutuzumab + Placebo (NCT02867384)
- 2025-02-27Results posted on the registry: Jennifer R. Brown, MD, PhD, Acalabrutinib + Umbralisib (NCT04624633)
- 2025-02-26Phase 3 first posted: Novartis Pharmaceuticals, Remibrutinib oral treatment + Ocrelizumab (NCT06846281)
- 2025-02-26Phase 3 first posted: Sandoz, CYB704 + Ocrevus-EU (NCT06847724)
- 2025-01-17Phase 3 first posted: Huashan Hospital, Obinutuzumab + CTX combined with Glucocorticoids (NCT06781944)
- 2024-11-22Phase 3 first posted: Amgen, Ocrelizumab (US) + Ocrelizumab (EU) (NCT06700343)
- 2024-11-08Results posted on the registry: Hoffmann-La Roche, Ocrelizumab (NCT04075266)
- 2024-11-06Phase 3 first posted: Hoffmann-La Roche, Ocrelizumab (NCT06675955)
- 2024-11-01Results posted on the registry: Novartis Pharmaceuticals, Ofatumumab (NCT04486716)
- 2024-07-31Results posted on the registry: Mayo Clinic, Obinutuzumab + Rituximab (NCT05376319)
- 2024-07-18Phase 3 first posted: Genmab, Epcoritamab + Rituximab (NCT06508658)
- 2024-05-24Phase 3 first posted: AbbVie, Venetoclax + Acalabrutinib (NCT06428019)
- 2024-04-30Results posted on the registry: BeiGene, Zanubrutinib + Obinutuzumab (NCT03332017)
- 2024-03-29Phase 3 first posted: National Cancer Institute (NCI), Mosunetuzumab + Rituximab (NCT06337318)
- 2024-02-28Phase 3 first posted: The Lymphoma Academic Research Organisation, Mosunetuzumab + Lenalidomide (NCT06284122)
- 2024-01-30Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Ifosfamide (NCT06230224)
- 2024-01-05Phase 3 first posted: Genmab, Epcoritamab + Prednisone (NCT06191744)
- 2023-11-28Phase 3 first posted: Regeneron Pharmaceuticals, Odronextamab + Lenalidomide (NCT06149286)
- 2023-11-18Results posted on the registry: City of Hope Medical Center, Acalabrutinib + Ublituximab (NCT04783415)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision